Consilient Health welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend elmiron® (pentosan polysulfate sodium) for bladder pain syndrome (BPS) within its marketing authorisation.
NICE has recommended that elmiron®, the only licensed oral medication for BPS with glomerulations or Hunner’s lesions (referred to as interstitial cystitis/BPS), is used in accordance with specified considerations.
The recommendation came after Consilient Health agreed a Patient Access Scheme with NICE which makes elmiron® available to the National Health Service (NHS).
Mr Jonathan Goddard, Consultant Urological Surgeon, Leicester General Hospital said: “This positive recommendation from NICE will allow patients with this chronic and difficult to treat condition to benefit from elmiron®, an effective and well-tolerated treatment for BPS”.
Susannah Fraser, Communication and Media Manager, Bladder Health UK said: “BPS is a debilitating condition and has a considerable detrimental impact on the individual’s lifestyle, ability to work, emotional health and relationships. Their quality of life is hugely compromised. For individuals to be able to access elmiron® on the NHS is really good news.”
Amanda Paxon, Consilient Health UK Country Manager Pharmaceuticals said: “This is a condition with a significant unmet clinical need and the company is delighted that elmiron® has been recommended for the treatment of IC/BPS”.